Vilacto Bio Inc. Developing Vilact® Skin Care Product with Carmen Electra
Oct 27, 2017
OTC Disclosure & News Service
COPENHAGEN, Denmark, Oct. 27, 2017 (GLOBE NEWSWIRE) — Vilacto Bio Inc. (OTCQB:VIBI), proudly announces that it has entered into a licensing agreement with Carmen Electra to develop a daily use skin cream – “Carmen Electra by Vilact®”. The skin cream is formulated to the highest clinical standards of Vilact® Skincare Products to exceed customer expectations.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/d6570050-3d53-4da3-83c5-5104450531a6
This licensing agreement with Carmen Electra is significant as it validates the marketing data, which says there is a demand for a natural skin care product such as the Company’s fully patented Lactoactive® (Lactoactive molecule) developed by the Company’s research team in Denmark. The Company’s skin cream is designed to harness the skin’s inner healing power to better protect itself against the environment while enabling cellular regeneration to maintain softer skin with a healthier, more youthful appearance.
“Vilacto Bio takes pride in our fully patented Lactoactive® that has earned its place in the upper echelon of high quality skin products and the recent endorsement of Carmen Electra is evidence of that,” states Gert Anderson, CEO of Vilacto Bio Inc.
Carmen Electra states, “I am always looking for new products to try out for my skin. After trying Vilacto Bio’s skin care line Vilact and falling in love with it, I knew I had to create my own line. I am super excited to introduce Carmen Electra by Vilact in the near future!”
About Vilacto Bio Inc.:
Vilacto Bio Inc. (OTCQB:VIBI), is a biotech company that has developed the now fully patented Lactoactive® (Lactoactive molecule) that in numerous studies have demonstrated above average effect treating conditions such as inflammatory diseases, diabetes, psoriasis, skin aging, and skin issues in different levels. We aim to further develop our Lactoactive® molecule for the purpose of increasing the quality of our retail and medical skin cream products as well as licensing out our Lactoactive® molecule for the pharmaceutical industry.
Vilacto Bio Inc.
Fabriksvej 48
4700 Naestved
Denmark
Gert Andersen
Phone: +1 646-893-7895
info@vilactobio.com
www.vilactobio.com
Forward-Looking Statements & Disclaimers:
The information in this Press Release includes certain “forward-looking” statements within the meaning of the Safe Harbor provisions of Federal Securities Laws, as that term is defined in section 27a of the United States Securities Act of 1933, as amended, and section 21e of the United States Securities Exchange Act of 1934, as amended. Statements in this document, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Investors are cautioned that such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including the future financial performance of the Company. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release, and the Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.
Copyright © 2017 GlobeNewswire. All Rights Reserved